3,5-dibromo-4-(4-methoxy-3-isopropylphenoxy) phenylacetic acid | 219692-35-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,5-dibromo-4-(4-methoxy-3-isopropylphenoxy) phenylacetic acid
• 英文别名: 3,5-dibromo-4-(4-methoxy-3-isopropylphenoxy)-phenylacetic acid；3,5-Dibromo-4-(4-methoxy-3-isopropylphenoxy)phenylacetic acid；3,5-dibromo-4-(3-isopropyl-4-methoxyphenoxy)phenylacetic acid；2-[3,5-dibromo-4-(4-methoxy-3-propan-2-ylphenoxy)phenyl]acetic acid
• CAS: 219692-35-0
• 化学式: C₁₈H₁₈Br₂O₄
• 分子量: 458.147
• InChiKey: WSOBAASPTWNZQK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3,5-dibromo-4-(4-methoxy-3-isopropylphenoxy) phenylacetic acid 在 benzyltrimethylazanium tetrachloro-λ³-iodanuide 作用下， 反应 1.0h， 以50%的产率得到3,5-dibromo-4-(4-hydroxy-5-chloro-3-isopropylphenoxy)phenylacetic acid
  参考文献：
  名称：

  [EN] BENZAMIDE OR PHENYLACETAMIDE DERIVATIVES USEFUL AS THYROID RECEPTOR LIGANDS
  [FR] NOUVEAUX COMPOSES

  摘要：

  公开号：

  WO2004007430A3

文献信息

• Thyroid receptor ligands and method
  申请人：Karo Bio AB

  公开号：US06465687B1

  公开（公告）日：2002-10-15

  Novel thyroid receptor ligands are provided which have the general formula (I) where R1 is alkyl of 1 to 4 carbons or cycloalkyl of 3 to 7 carbons; R2 and R3 are the same or different and are hydrogen, halogen, alkyl of 1 to 3 carbons or cycloalkyl of 3 to 5 carbons, at least one of R2 and R3 being other than hydrogen; n is an integer from 0 to 4; R4 is an aliphatic hydrocarbon, an aromatic hydrocarbon, carboxylic acid ester thereof, alkenyl carboxylic acid or ester thereof, hydroxy, halogen, cyano, or a phosphonic acid or an ester thereof, or a pharmaceutically acceptible salt thereof. A method for treating diseases associated with metabolism dysfunction or which are dependent on the expression of a T3 regulated gene, such as obesity, hypercholesterolemia, osteoporosis, hypothyroidism, and goiter, is also provided.

  提供了具有一般式(I)的新型甲状腺受体配体 其中R1是1至4个碳原子的烷基或3至7个碳原子的环烷基；R2和R3相同或不同，是氢、卤素、1至3个碳原子的烷基或3至5个碳原子的环烷基，R2和R3中至少有一个不是氢；n是从0到4的整数；R4是脂肪烃、芳香烃、羧酸酯、烯基羧酸或其酯、羟基、卤素、氰基、磷酸或其酯，或其药用可接受盐。还提供了一种治疗与代谢功能障碍或依赖T3调节基因表达的疾病有关的方法，如肥胖症、高胆固醇血症、骨质疏松症、甲状腺功能减退症和甲状腺肿。
• Novel thyroid receptor ligands and method II
  申请人：Hangeland Jon

  公开号：US20050282872A1

  公开（公告）日：2005-12-22

  New thyroid receptor ligands are provided which have general formula (I) in which: n is an integer from 0 to 4; R 1 is halogen, trifluoromethyl, or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 7 carbons; R 2 and R 3 are the same or differential hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 5 carbons, at least one of R 2 and R 3 being other than hydrogen; R 4 is a carboxylic acid thereof; or when n is equal to or greater than one, R 4 may be heteroaromatic moiety which may be substituted or unsubstituted, or an amine (NR′R″). R 5 is hydrogen or an acyl (such as acetyl or benzoyl) or other group capable of bioconversion to generate the free phenol structure (wherein R 5 —H). In addition, a method is provided for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependant upon the expression of a T 3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount. Examples of such diseases associated with metabolism dysfunction or are dependent upon the expression of a T 3 regulated gene include obesity, hypercholesterolemia, atherosclerosis, cardiac arrhythmias, depression, osteoporosis, hypothyroidism, goiter, thyroid cancer as well as glaucoma, congestive heart failure and skin disorders.

  提供了新的甲状腺受体配体，其具有以下通式（I）：其中：n是从0到4的整数；R1是卤素、三氟甲基或1至6个碳原子的烷基或3至7个碳原子的环烷基；R2和R3相同或不同，是氢、卤素、1至4个碳原子的烷基或3至5个碳原子的环烷基，其中至少有一个是氢之外的其他基团；R4是其羧酸；或当n等于或大于1时，R4可以是杂环芳基团，可能被取代或未取代，或胺（NR′R″）。R5是氢或酰基（如乙酰基或苯甲酰基）或其他能够生物转化以生成游离酚结构（其中R5-H）的基团。此外，提供了一种方法，用于预防、抑制或治疗与代谢功能障碍相关或依赖于T3调节基因表达的疾病，其中上述描述的化合物以治疗有效剂量给予。与代谢功能障碍相关或依赖于T3调节基因表达的疾病的例子包括肥胖症、高胆固醇血症、动脉粥样硬化、心律失常、抑郁症、骨质疏松症、甲状腺功能减退症、甲状腺肿、甲状腺癌以及青光眼、充血性心力衰竭和皮肤疾病。
• Novel compounds
  申请人：Garg Neeraj

  公开号：US20060135614A1

  公开（公告）日：2006-06-22

  This invention relates to novel compounds, which are thyroid receptor ligands, and to methods of preparing such compounds. In addition, a method is provided for preventing, inhibiting or treating diseases or disorders associated with metabolism dysfunction or which are dependent upon the expression of a T3 regulated gene, wherein a compound as described herein is administered in a therapeutically effective amount.

  本发明涉及一种新型化合物，它们是甲状腺受体配体，并提供了制备这些化合物的方法。此外，本发明还提供了一种预防、抑制或治疗与代谢功能紊乱相关的疾病或随着T3调节基因表达而产生的疾病或障碍的方法，其中所述的化合物以治疗有效量的方式给予。
• Benzamide derivatives as thyroid receptor ligands
  申请人：Karo Bio AB

  公开号：US07153997B2

  公开（公告）日：2006-12-26

  This invention relates to novel compounds, which are thyroid receptor ligands, and to methods of preparing such compounds. In addition, a method is provided for preventing, inhibiting or treating diseases or disorders associated with metabolism dysfunction or which are dependent upon the expression of a T3 regulated gene, wherein a compound as described herein is administered in a therapeutically effective amount.

  本发明涉及新型化合物，它们是甲状腺受体配体，并涉及制备这种化合物的方法。此外，提供了一种方法，用于预防、抑制或治疗与代谢功能障碍或依赖于T3调节基因表达的疾病或疾病，其中以本文所述的化合物以治疗有效量的方式给予。
• NOVEL THYROID RECEPTOR LIGANDS AND METHOD
  申请人：KARO BIO AB

  公开号：EP1000008B1

  公开（公告）日：2003-06-25